OZEMPIC Rx

Select the drug indication to add to your list

OZEMPIC

Diabetes
Only 4 drugs may be compared at once

Generic Name and Formulations:

Semaglutide 2mg/1.5mL (1.34mg/mL); per pen injector; soln for SC inj.

Company:

Novo Nordisk

premium monograph ?Access to resources provided by Novo Nordisk Medical Affairs
Search for comprehensive medical information for OZEMPIC
Search Premium Monographs

Have a product inquiry? Access comprehensive and accurate pharmaceutical Medical Information

Select therapeutic use:

Indications for OZEMPIC:

As adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

Limitations Of use:

Not recommended as first-line therapy for patients inadequately controlled on diet and exercise. Not studied with a history of pancreatitis. Not a substitute for insulin. Not for treating type 1 diabetes or diabetic ketoacidosis.

Adult:

Give by SC inj in abdomen, thigh, or upper arm; rotate inj sites. Initially 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for at least 4 weeks; if additional control needed, may increase to 1mg once weekly (max).

Dosing - Missed Dose Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Prescribing Information

Additional Information

References

Children:

<18yrs: not established.

Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Boxed Warning:

Risk of thyroid C-cell tumors.

Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. Do not reuse or share pens or needles between patients. Monitor renal function when initiating or escalating dose. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Discontinue if hypersensitivity reactions occur. Pregnancy. Females of reproductive potential: discontinue ≥2 months prior to planned pregnancy. Nursing mothers.

Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Interactions:

Concomitant insulin; administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); caution.

Adverse Reactions:

Nausea, vomiting, diarrhea, abdominal pain, constipation; rare: pancreatitis, hypersensitivity reactions.

Generic Availability:

NO

How Supplied:

Single-patient-use pre-filled pen (0.25mg or 0.5mg per inj)—1; (1mg per inj)—2

More Info:

Switching from GLP-1 Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Summary

Switching from Once- or Twice-Daily GLP-1 RAs to Ozempic® 

Switching from Once-Weekly GLP-1 RAs to Ozempic® 

Additional Information

References

Allergic Reactions Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Summary

Formulation

Background on Immunogenic Reactions

Skin Testing

Treatment of Allergic Reactions

Use of Ozempic® in a Patient Allergic to Other Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists or Insulin

Additional Information

Appendix 1

References

Pharmacokinetics, Pharmacodynamics Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Summary

Pharmacokinetic (PK) and Pharmacodynamic (PD) Studies

Additional Information

References

Mechanisms of Protraction and Action Powered by Novo Nordisk Medical Affairs

The below information is supplied to you as a professional service in response to your specific request. This letter is meant to supplement information you have gathered from other sources and is not intended to promote or advocate the use of Novo Nordisk products in any manner other than described in the Prescribing Information.

Mechanism of Protraction

Mechanism of Action

Additional Information

References

OZEMPIC 1 pen of 0.25mg/0.5mg cartons (Qty:1)

appx. price $703.00